Study: For complex cases of NMOSD, Ultomiris found safe, effective
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
Ultomiris safely and effectively reduces relapse risk in complex NMOSD cases and may be safe in combination with rituximab for short periods.| Neuromyelitis News
Using noninvasive eye scans may help clinicians determine if patients have NMOSD or MS, particularly in early disease stages, a study found.| Neuromyelitis News
A review of nearly 100 articles found that muscle problems are relatively common in NMOSD, affecting more than one-third of patients.| Neuromyelitis News
The gut hormone GLP-1 may drive brain inflammation in NMOSD patients, leading to nausea, vomiting, or hiccups, called area postrema syndrome.| Neuromyelitis News
Bilateral vision loss, the use of a walking aid, fatigue, and depression predict employment loss after a NMOSD diagnosis, a study shows.| Neuromyelitis News
Ultomiris, an approved infusion therapy for neuromyelitis optica spectrum disorder, is closer to being eligible for reimbursement in Canada.| Neuromyelitis News
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg, where her research focused on the role of inflammation in acute myeloid leukemia. With a deep passion for...| Neuromyelitis News
Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the...| Neuromyelitis News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Neuromyelitis News
The activity of an immune-regulating protein is significantly lower just before or during a relapse in people with neuromyelitis optica spectrum disorder (NMOSD), a recent study has found. This discovery could lead to new ways to monitor disease activity and develop treatments. The protein, called the aryl hydrocarbon receptor (AHR), is a ligand-activated transcription factor. […] The post AHR protein may be a biomarker for NMOSD relapses appeared first on Neuromyelitis News.| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
Long-term use of the approved therapy Enspryng (satralizumab) safely and effectively prevented relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who have antibodies against aquaporin-4 (AQP4). That’s according to up to 8.8 years of pooled data from two placebo-controlled Phase 3 clinical trials — SAkuraStar (NCT02073279) and SAkuraSky (NCT02028884) — and their now-completed open-label extension study, […] The post Enspryng prevents relapses in NMOSD for up to ne...| Neuromyelitis News – The Web's Daily Resource for Neuromyelitis Optica News
Nearly all adults with neuromyelitis optica spectrum disorder NMOSD) experience headaches, especially migraines, a study in Iran shows.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Steve Bryson is a science writer for Neuromyelitis News with a PhD in biochemistry. He covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
